Recipharm receives approval for the manufacture of a new microbiome-based therapeutic
Recipharm receives regulatory approval for the manufacture of a microbiome-based product for the prevention of Clostridioides difficile recurrent infection, under GenIbet Biopharmaceuticals and Seres Therapeutics.
The leading CDMO in biopharmaceuticals Recipharm has received approval from the US FDA for its auxiliary partner GenIbet Biopharmaceuticals to manufacture its orally-administered fecal microbiota product, VOWST.
VOWST is used to prevent Clostridioides difficile recurrent infection (CDI) in adults who have already received antibacterial treatment for the infection. CDI is one of the biggest microbial health risks in the USA according to the Centers for Disease Control and Prevention, responsible for around 30,000 deaths each year.
Recipharm will oversee the manufacturing of the microbiota product at the GenIbet site in Oeiras, Portugal, in tandem with Seres Therapeutics.
Raquel Fortunato, CEO of GenIbet, commented:
“FDA’s approval is a major development in the biologics market. It will help shift the perception of microbiome medicines and open the door for new opportunities for patients around the world.
I would like to thank colleagues, past and present, who have been involved in the VOWST project. Their hard work and perseverance over almost ten years have enabled this major milestone which has the potential to improve patients’ health and save lives. I can’t think of a better example to illustrate our mission, to be the bridge between innovators and patients.”
Under Recipharm, GenIbet Biopharmaceuticals is experienced in manufacturing of biological clinical trial material, viral vectors, RNA, and microbiome therapeutics in particular. In 2014 GenIbet began supporting Seres Therapeutics, specialising in clinical trial supply, process validation, and BLA submission, from there they progressed to enabling the VOWST Tech Transfer and taking over the GMP manufacturing of the product.
GenIbet Biopharmaceuticals is known for developing novel production processes in the preclinical and Phase I and II clinical trial stages.
The recent FDA approval will mean that Recipharm can expand its manufacturing capabilities and increase the output of novel modalities for manufacturing biologics.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Pharmapack 2024 - From the Floor
Paris once again welcomes Europe’s leading trade show in pharmaceutical packaging and drug delivery innovation. Join our content team as Pharmapack 2024 opens its doors to leading experts and innovators in pharmaceutical packaging and drug delive... -
News On Track at Pharmapack 2024 - The Track Sponsor interview: BD Pharmaceuticals
January 2024 brings both a new year and Europe’s leading packaging and drug delivery event. Bringing the world’s experts in pharmaceutical packaging together in Paris, France, Pharmapack 2024 brings exciting opportunities to learn and colla... -
News CPHI Pharma Awards 2023 – API Development and Innovation Winners: Snapdragon Chemistry, a Cambrex Company
After another year of impressive nominations for the CPHI Pharma Awards our winners were announced at CPHI Barcelona in October. In this series of interviews, we speak to the teams behind the award-winning projects, concepts, and technologies. -
News PharmaKure gains authorisation for next stage testing on Alzheimer's treatment
Clinical stage pharmaceutical company PharmaKure gains permission from UK authorities to enter into further testing for PK051 for the treatment of patients with mild cognitive impairment associated with Alzheimer's disease. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News Navigating the Future: Challenges and Opportunities in Pharma Innovation and Investment – CPHI Barcelona 2023 Roundtable Report
In this comprehensive downloadable report, hear from a range of experts in finance and investment in the pharma industry on what investment trends will be shaping the future of the industry, in Catalonia, and the wider world. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance